Analysis of risk signals for Viloxazine in the treatment of attention deficit hyperactivity disorder based on the FAERS database

CONCLUSION: Viloxazine has shown efficacy and tolerability but poses potential safety risks, particularly regarding mood, behavior, and sensory processing. Ongoing monitoring and further studies are needed.

via https://pubmed.ncbi.nlm.nih.gov/40274110/?utm_source=Other&utm_medium=rss&utm_campaign=None&utm_content=1L37KAMf2b_g4WEK3LmdFuKZu9pO3cN7u4ZmO9PPCPeBLMIw1q&fc=None&ff=20250509010905&v=2.18.0.post9+e462414